Novo Nordisk has announced plans to cut 9,000 jobs to refocus the business on its core diabetes and obesity drugs. The move affects approximately 5,000 positions in Denmark and amounts to an 11% reduction in its global workforce of 78,400 employees.
The decision will be a blow
